33 research outputs found

    OSTEOPETROSIS AND ENDOPROSTHETICS - CLINICAL OBSERVATIONS

    Get PDF
    Aim - to evaluate the efficacy of treatment of secondary arthrosis of the coxofemoral joints associated with osteopetrosis using arthroplasty. Materials and methods - clinical observation of two cases of treatment of patients with autosomal dominant form of osteopetrosis who underwent total hip arthroplasty at the Federal State Budgetary Institution Federal Center of Traumatology, Orthopaedics and Endoprosthesis replacement (Cheboksary). Results. We obtained positive results and patient’s satisfaction with the function of prosthetic joints with a follow-up period of 3.5 years. This method of treatment showed its efficacy during the specified follow-up period. Arthroplasty provides relief from pain, improved quality of life and increased mobility of the joint for patients with coxarthrosis associated with osteopetrosis

    Optimal treatment methods of infectious complications in cases of large joint replacement arthroplasty in modern conditions

    Get PDF
    Research objective: to choose optimal treatment methods in conditions of Federal Centers of high-technology medical carebased on the analysis of infectious complications in cases of large joint replacement arthroplasty. Materials and methods. In the Federal State Publicly Funded Institution β€œFederal Center of Traumatology, Orthopedics and Replacement Arthroplasty” in Cheboksary city in the period from 2009 to 2014 there weremade 20761 large joint replacement operations. The incidence rate of deep infectious complicationsamounted to 0.3%. The average age of patients who had infectious complications was 61.2Β± 12.3 years old, and the male to female ratio was 1:2. Infectious complication risk factors have been evaluated using the continuous method, and the species composition of selected microflora have been studied. Based on the analysis of surgical intervention approaches the optimal method of surgical treatment has been determined. Results. The main predisposing infectious complication risk factors were chronic infection sites, diabetes, obesity, systemic inflammatory diseases, previous intra-articular administration of medicines, blood transfusions, repeated surgical manipulations in the area of the planned surgical intervention, as well as hematomas in the periprosthetic area identified in the postoperative period. The main germ of infectious complications is represented by gram-positive organisms, and the leading role belongs to staphylococci (52%). When identifying infection in the operated jointat the Center, such priority treatment strategiesas a two-stage replacement arthroplasty with long interval" (70.5%), single-stage revision surgery (23.5%), and three-stage revision surgery (6 % ) were used. Two-stage replacement arthroplasty with β€œlong interval” is an efficient treatment, as well as it is economically feasible. It is necessary to take into account the duration of an antibioticrelease from the cement spacer. Reduction of the period between reimplantations significantly reduces the proportion of re-revisions (from 9% to 4.5% , p<0.05), improves long-term results and increases the treatmentmotivation of patients.ЦСль исслСдования: Π½Π° основС Π°Π½Π°Π»ΠΈΠ·Π° ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΎΠ½Π½Ρ‹Ρ… ослоТнСний ΠΏΡ€ΠΈ эндопротСзировании ΠΊΡ€ΡƒΠΏΠ½Ρ‹Ρ… суставов Π²Ρ‹Π±Ρ€Π°Ρ‚ΡŒ ΠΎΠΏΡ‚ΠΈΠΌΠ°Π»ΡŒΠ½Ρ‹Π΅ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹ лСчСния Π² условиях Π€Π΅Π΄Π΅Ρ€Π°Π»ΡŒΠ½Ρ‹Ρ… Π¦Π΅Π½Ρ‚Ρ€ΠΎΠ² высокотСхнологичной мСдицинской ΠΏΠΎΠΌΠΎΡ‰ΠΈ. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π’ Π€Π“Π‘Π£ Β«Π€ Π¦ ВОЭ Β» ΠœΠΈΠ½Π·Π΄Ρ€Π°Π²Π° России (Π³. ЧСбоксары) Π·Π° ΠΏΠ΅Ρ€ΠΈΠΎΠ΄ с 2009 ΠΏΠΎ 2014 Π³Π³. Π±Ρ‹Π»ΠΎ ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½ΠΎ 20 761 ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΉ ΠΏΠΎ ΡΠ½Π΄ΠΎΠΏΡ€ΠΎΡ‚Π΅Π·ΠΈΡ€ΠΎΠ²Π°Π½ΠΈΡŽ ΠΊΡ€ΡƒΠΏΠ½Ρ‹Ρ… суставов. Частота возникновСния Π³Π»ΡƒΠ±ΠΎΠΊΠΈΡ… ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΎΠ½Π½Ρ‹Ρ… ослоТнСний составила 0,3%. Π‘Ρ€Π΅Π΄Π½ΠΈΠΉ возраст ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΎΠ½Π½Ρ‹ΠΌΠΈ ослоТнСниями составил 61,2+12,3 Π³ΠΎΠ΄Π°, ΡΠΎΠΎΡ‚Π½ΠΎΡˆΠ΅Π½ΠΈΠ΅ ΠΌΡƒΠΆΡ‡ΠΈΠ½ ΠΈ ΠΆΠ΅Π½Ρ‰ΠΈΠ½ 1:2. Π‘ΠΏΠ»ΠΎΡˆΠ½Ρ‹ΠΌ ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΎΡ†Π΅Π½ΠΊΠ° Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΎΠ² риска развития ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΎΠ½Π½Ρ‹Ρ… ослоТнСний, ΠΈΠ·ΡƒΡ‡Π΅Π½ Π²ΠΈΠ΄ΠΎΠ²ΠΎΠΉ состав Π²Ρ‹Π΄Π΅Π»Π΅Π½Π½ΠΎΠΉ ΠΌΠΈΠΊΡ€ΠΎΡ„Π»ΠΎΡ€Ρ‹. На основании Π°Π½Π°Π»ΠΈΠ·Π° Ρ‚Π°ΠΊΡ‚ΠΈΠΊΠΈ ΠΎΠΏΠ΅Ρ€Π°Ρ‚ΠΈΠ²Π½ΠΎΠ³ΠΎ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π° ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½ ΠΎΠΏΡ‚ΠΈΠΌΠ°Π»ΡŒΠ½Ρ‹ΠΉ ΠΌΠ΅Ρ‚ΠΎΠ΄ хирургичСского лСчСния. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. ΠžΡΠ½ΠΎΠ²Π½Ρ‹ΠΌΠΈ ΠΏΡ€Π΅Π΄Ρ€Π°ΡΠΏΠΎΠ»Π°Π³Π°ΡŽΡ‰ΠΈΠΌΠΈ Ρ„Π°ΠΊΡ‚ΠΎΡ€Π°ΠΌΠΈ риска Π² Ρ€Π°Π·Π²ΠΈΡ‚ΠΈΠΈ ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΎΠ½Π½Ρ‹Ρ… ослоТнСний явились ΠΎΡ‡Π°Π³ΠΈ хроничСской ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ, сахарный Π΄ΠΈΠ°Π±Π΅Ρ‚, ΠΎΠΆΠΈΡ€Π΅Π½ΠΈΠ΅, систСмныС Π²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Π΅ заболСвания, ΠΏΡ€Π΅Π΄ΡˆΠ΅ΡΡ‚Π²ΡƒΡŽΡ‰Π΅Π΅ внутрисуставноС Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ лСкарствСнных срСдств, гСматрансфузии, Π½Π΅ΠΎΠ΄Π½ΠΎΠΊΡ€Π°Ρ‚Π½Ρ‹Π΅ хирургичСскиС манипуляции области ΠΏΠ»Π°Π½ΠΈΡ€ΡƒΠ΅ΠΌΠΎΠ³ΠΎ хирургичСского Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²Π°, Π° Ρ‚Π°ΠΊΠΆΠ΅ Π½Π°Π»ΠΈΡ‡ΠΈΠ΅ Π³Π΅ΠΌΠ°Ρ‚ΠΎΠΌ Π² ΠΏΠ΅Ρ€ΠΈΠΏΡ€ΠΎΡ‚Π΅Π·Π½ΠΎΠΉ Π·ΠΎΠ½Π΅, выявлСнныС Π² послСопСрационном ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π΅. Основной Π²ΠΎΠ·Π±ΡƒΠ΄ΠΈΡ‚Π΅Π»ΡŒ ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΎΠ½Π½Ρ‹Ρ… ослоТнСний прСдставлСн Π“Ρ€Π°ΠΌΠΌ ΠΏΠΎΠ»ΠΎΠΆΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌΠΈ ΠΌΠΈΠΊΡ€ΠΎΠΎΡ€Π³Π°Π½ΠΈΠ·ΠΌΠ°ΠΌΠΈ, вСдущая Ρ€ΠΎΠ»ΡŒ ΠΈΠ· ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… ΠΏΡ€ΠΈΠ½Π°Π΄Π»Π΅ΠΆΠΈΡ‚ стафилококкам (52%). ΠŸΡ€ΠΈ выявлСнии ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ процСсса Π² ΠΎΠΏΠ΅Ρ€ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠΌ суставС приоритСтная Ρ‚Π°ΠΊΡ‚ΠΈΠΊΠ° лСчСния Π² Π¦Π΅Π½Ρ‚Ρ€Π΅ состояла Π² двухэтапном эндопротСзировании с Β«Π΄Π»ΠΈΠ½Π½Ρ‹ΠΌ ΠΈΠ½Ρ‚Π΅Ρ€Π²Π°Π»ΠΎΠΌΒ» (70,5%), одноэтапноС Ρ€Π΅Π²ΠΈΠ·ΠΈΠΎΠ½Π½ΠΎΠ΅ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²ΠΎ составило 23,5%, трСхэтапноС Ρ€Π΅Π²ΠΈΠ·ΠΈΠΎΠ½Π½ΠΎΠ΅ Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²ΠΎ - 6%. ДвухэтапноС эндопротСзированиС с Β«Π΄Π»ΠΈΠ½Π½Ρ‹ΠΌ ΠΈΠ½Ρ‚Π΅Ρ€Π²Π°Π»ΠΎΠΌΒ» являСтся эффСктивным ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ лСчСния, Π° Ρ‚Π°ΠΊΠΆΠ΅ экономичСски цСлСсообразным. ΠŸΡ€ΠΈ этом Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΠΎ ΡƒΡ‡ΠΈΡ‚Ρ‹Π²Π°Ρ‚ΡŒ Π΄Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ высвобоТдСния Π°Π½Ρ‚ΠΈΠ±ΠΈΠΎΡ‚ΠΈΠΊΠ° ΠΈΠ· Ρ†Π΅ΠΌΠ΅Π½Ρ‚Π½ΠΎΠ³ΠΎ спСйсСра. Π‘ΠΎΠΊΡ€Π°Ρ‰Π΅Π½ΠΈΠ΅ срока ΠΌΠ΅ΠΆΠ΄Ρƒ рСимплантациями достовСрно сниТаСт долю Ρ€Π΅Ρ€Π΅Π²ΠΈΠ·ΠΈΠΉ (с 9% Π΄ΠΎ 4,5%, Ρ€<0,05), ΡƒΠ»ΡƒΡ‡ΡˆΠ°Π΅Ρ‚ долгосрочныС Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹, ΠΏΠΎΠ²Ρ‹ΡˆΠ°Π΅Ρ‚ ΠΌΠΎΡ‚ΠΈΠ²Π°Ρ†ΠΈΡŽ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² ΠΊ Π»Π΅Ρ‡Π΅Π½ΠΈΡŽ

    Thrombosis: a note of caution! What a district therapist important to know about for patients after orthopedic surgery

    Get PDF
    The purpose of this article is to attract the attention of primary care physicians to the problem of prevention of venous thromboembolic complications (VTEC) in patients after orthopaedic surgeries. The article presents a complex approach to the prevention of VTEC in patients after arthroplasty of large joints, and provides a brief overview of oral anticoagulants used in modern clinical practice, depending on the level of venoocclusive disease on the one hand and development of undesirable side effects on the other hand. Taking into account the fact, that the average time of incidence of thromboembolic complications (VTEC) after arthroplasty of large joints is from 12 to 34 days, it is necessary for outpatient doctors to participate actively in prophylaxis of VTEC, early detection of clinical symptoms of thromboembolic complications, as well as in evaluation of undesirable side effects arising on the background of anticoagulants intake. This, in turn, will allow minimizing the mortality rate in patients of all age groups after orthopaedic surgeries.ЦСлью Π΄Π°Π½Π½ΠΎΠΉ ΡΡ‚Π°Ρ‚ΡŒΠΈ являСтся ΠΏΡ€ΠΈΠ²Π»Π΅Ρ‡Π΅Π½ΠΈΠ΅ внимания Π²Ρ€Π°Ρ‡Π΅ΠΉ ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎΠ³ΠΎ Π·Π²Π΅Π½Π° ΠΊ ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΠ΅ ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠΈ Π²Π΅Π½ΠΎΠ·Π½Ρ‹Ρ… тромбоэмболичСских ослоТнСний (Π’Π’Π—Πž) Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² послС ортопСдичСских ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΉ. ΠŸΡ€Π΅Π΄ΡΡ‚Π°Π²Π»Π΅Π½ комплСксный ΠΏΠΎΠ΄Ρ…ΠΎΠ΄ ΠΊ ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠ΅ Π’Π’Π­Πž Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² послС артропластики ΠΊΡ€ΡƒΠΏΠ½Ρ‹Ρ… суставов, ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½ ΠΊΡ€Π°Ρ‚ΠΊΠΈΠΉ ΠΎΠ±Π·ΠΎΡ€ ΠΎΡ€Π°Π»ΡŒΠ½Ρ‹Ρ… антикоагулянтов, ΠΏΡ€ΠΈΠΌΠ΅Π½ΡΡŽΡ‰ΠΈΡ…ΡΡ Π² соврСмСнной клиничСской ΠΏΡ€Π°ΠΊΡ‚ΠΈΠΊΠ΅ Π² зависимости ΠΎΡ‚ уровня окклюзионного пораТСния Π²Π΅Π½ с ΠΎΠ΄Π½ΠΎΠΉ стороны ΠΈ Ρ€Π°Π·Π²ΠΈΡ‚ΠΈΠ΅ΠΌ Π½Π΅ΠΆΠ΅Π»Π°Ρ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΏΠΎΠ±ΠΎΡ‡Π½Ρ‹Ρ… Ρ€Π΅Π°ΠΊΡ†ΠΈΠΉ с Π΄Ρ€ΡƒΠ³ΠΎΠΉ. Π‘ ΡƒΡ‡Π΅Ρ‚ΠΎΠΌ Ρ‚ΠΎΠ³ΠΎ, Ρ‡Ρ‚ΠΎ срСдниС сроки возникновСния тромбоэмболичСских ослоТнСний (ВЭО) послС артропластики ΠΊΡ€ΡƒΠΏΠ½Ρ‹Ρ… суставов ΡΠΎΡΡ‚Π°Π²Π»ΡΡŽΡ‚ ΠΎΡ‚ 12 Π΄ΠΎ 34 Π΄Π½Π΅ΠΉ, Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΠΎ Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΠ΅ участиС Π²Ρ€Π°Ρ‡Π΅ΠΉ Π°ΠΌΠ±ΡƒΠ»Π°Ρ‚ΠΎΡ€Π½ΠΎ-поликлиничСского Π·Π²Π΅Π½Π° Π² ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠ΅ Π’Π’Π­Πž, Π² своСврСмСнном выявлСнии клиничСских симптомов ВЭО ΠΈ ΠΎΡ†Π΅Π½ΠΊΠ΅ Π½Π΅ΠΆΠ΅Π»Π°Ρ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΏΠΎΠ±ΠΎΡ‡Π½Ρ‹Ρ… Ρ€Π΅Π°ΠΊΡ†ΠΈΠΉ Π½Π° Ρ„ΠΎΠ½Π΅ ΠΏΡ€ΠΈΠ΅ΠΌΠ° антикоагулянтов. Π­Ρ‚ΠΎ Π² свою ΠΎΡ‡Π΅Ρ€Π΅Π΄ΡŒ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ‚ ΠΌΠΈΠ½ΠΈΠΌΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Ρ‚ΡŒ Π»Π΅Ρ‚Π°Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² всСх возрастных Π³Ρ€ΡƒΠΏΠΏ послС ортопСдичСских ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΉ

    Diagnostically significant differences septic and aseptic instability of endoprosthesis components during arthroplasty of large joints

    Get PDF
    The purpose of the work is to analyze the results of laboratory, microbiological and instrumental studies to search for screening criteria for the difference between aseptic and septic instability of endoprosthesis components after knee and hip joint arthroplasty. The materials contained 146 cases of revision arthroplasty of the knee and hip joints, performed under the conditions of Federal State Budgetary Institution Federal Center of Traumatology, Orthopedics and endoprosthesis replacement of Ministry of Health of the Russian Federation (Cheboksary) for a 3-year period, including cases of aseptic instability - 69, septic instability-77. By methods for laboratory diagnosis were used to evaluate the blood levels of leukocytes, stab neutrophils, ESR, C-reactive protein (CRP), presepsin, procalcitonin, D-dimer, interleukin-6. Using ultrasound (ultrasonic) examination of the periprosthetic zone, the presence of fluid, granulation tissue in the joint cavity, altered lymph nodes was determined. Before the operation, the level of cytosis and cellular composition were determined in the synovial fluid; tissue bioptates, removed components of implants (after ULTRASONIC treatment) with sowing on the microflora were studied intraoperatively. Intraoperative tissue biopsies were used to make smears-prints on the glass, with gram staining, estimating the number of leukocytes and neutrophils in the field of vision. Results. Determination of indicators of ESR, presepsin and interleukin-6, the level of which goes beyond the generally recognized normal values in the presence of infection, can be recommended as a screening test in the diagnosis of the infectious nature of instability of the components of the endoprosthesis of large joints. The second stage of differential diagnosis of septic and aseptic instability can be the detection of lymphadenopathy. The third (final) stage of determining the infectious nature of instability is an invasive technique to determine the level of cytosis with the calculation of neutrophils in the synovial fluid.ЦСль Ρ€Π°Π±ΠΎΡ‚Ρ‹ - Π°Π½Π°Π»ΠΈΠ· Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚ΠΎΠ² Π»Π°Π±ΠΎΡ€Π°Ρ‚ΠΎΡ€Π½Ρ‹Ρ…, микробиологичСских ΠΈ ΠΈΠ½ΡΡ‚Ρ€ΡƒΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½Ρ‹Ρ… исслСдований для поиска скрининг-ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠ΅Π² отличия асСптичСской ΠΈ сСптичСской Π½Π΅ΡΡ‚Π°Π±ΠΈΠ»ΡŒΠ½ΠΎΡΡ‚ΠΈ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚ΠΎΠ² эндопротСза послС артропластики ΠΊΠΎΠ»Π΅Π½Π½Ρ‹Ρ… ΠΈ Ρ‚Π°Π·ΠΎΠ±Π΅Π΄Ρ€Π΅Π½Π½Ρ‹Ρ… суставов. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Π°ΠΌΠΈ послуТили 146 случаСв Ρ€Π΅Π²ΠΈΠ·ΠΈΠΎΠ½Π½ΠΎΠΉ артропластики ΠΊΠΎΠ»Π΅Π½Π½Ρ‹Ρ… ΠΈ Ρ‚Π°Π·ΠΎΠ±Π΅Π΄Ρ€Π΅Π½Π½Ρ‹Ρ… суставов, Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½Π½ΠΎΠΉ Π² условиях Π€Π΅Π΄Π΅Ρ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ государствСнного Π±ΡŽΠ΄ΠΆΠ΅Ρ‚Π½ΠΎΠ³ΠΎ учрСТдСния Β«Π€Π΅Π΄Π΅Ρ€Π°Π»ΡŒΠ½Ρ‹ΠΉ Ρ†Π΅Π½Ρ‚Ρ€ Ρ‚Ρ€Π°Π²ΠΌΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΈΠΈ, ΠΎΡ€Ρ‚ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΈ эндопротСзирования» ΠœΠΈΠ½ΠΈΡΡ‚Π΅Ρ€ΡΡ‚Π²Π° здравоохранСния российской Π€Π΅Π΄Π΅Ρ€Π°Ρ†ΠΈΠΈ (Π³. ЧСбоксары) Π·Π° 3-Π»Π΅Ρ‚Π½ΠΈΠΉ ΠΏΠ΅Ρ€ΠΈΠΎΠ΄, ΠΈΠ· Π½ΠΈΡ… случаСв асСптичСской Π½Π΅ΡΡ‚Π°Π±ΠΈΠ»ΡŒΠ½ΠΎΡΡ‚ΠΈ - 69, сСптичСской Π½Π΅ΡΡ‚Π°Π±ΠΈΠ»ΡŒΠ½ΠΎΡΡ‚ΠΈ - 77. ΠœΠ΅Ρ‚ΠΎΠ΄Π°ΠΌΠΈ Π»Π°Π±ΠΎΡ€Π°Ρ‚ΠΎΡ€Π½ΠΎΠΉ диагностики ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠ»Π°ΡΡŒ ΠΎΡ†Π΅Π½ΠΊΠ° содСрТания Π² ΠΊΡ€ΠΎΠ²ΠΈ Π»Π΅ΠΉΠΊΠΎΡ†ΠΈΡ‚ΠΎΠ², палочкоядСрных Π½Π΅ΠΉΡ‚Ρ€ΠΎΡ„ΠΈΠ»ΠΎΠ², БОЭ, Π‘-Ρ€Π΅Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° (Π‘Π Π‘), прСсСпсина, ΠΏΡ€ΠΎΠΊΠ°Π»ΡŒΡ†ΠΈΡ‚ΠΎΠ½ΠΈΠ½Π°, Π”-Π΄ΠΈΠΌΠ΅Ρ€Π°, ΠΈΠ½Ρ‚Π΅Ρ€Π»Π΅ΠΉΠΊΠΈΠ½Π°-6. Π‘ ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ ΡƒΠ»ΡŒΡ‚Ρ€Π°Π·Π²ΡƒΠΊΠΎΠ²ΠΎΠ³ΠΎ (Π£Π—) исслСдования ΠΏΠ΅Ρ€ΠΈΠΏΡ€ΠΎΡ‚Π΅Π·Π½ΠΎΠΉ Π·ΠΎΠ½Ρ‹ опрСдСляли Π½Π°Π»ΠΈΡ‡ΠΈΠ΅ Тидкости, грануляционной Ρ‚ΠΊΠ°Π½ΠΈ Π² полости сустава, ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½Ρ‹Ρ… лимфатичСских ΡƒΠ·Π»ΠΎΠ². Π΄ΠΎ ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΈ Π² синовиальной Тидкости опрСдСляли ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ Ρ†ΠΈΡ‚ΠΎΠ·Π° ΠΈ ΠΊΠ»Π΅Ρ‚ΠΎΡ‡Π½Ρ‹ΠΉ состав; ΠΈΠ½Ρ‚Ρ€Π°ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΎΠ½Π½ΠΎ исслСдовались Ρ‚ΠΊΠ°Π½Π΅Π²Ρ‹Π΅ Π±ΠΈΠΎΠΏΡ‚Π°Ρ‚Ρ‹, ΡƒΠ΄Π°Π»Π΅Π½Π½Ρ‹Π΅ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚Ρ‹ ΠΈΠΌΠΏΠ»Π°Π½Ρ‚ΠΎΠ² (послС Π£Π— ΠΎΠ±Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ) с посСвом Π½Π° ΠΌΠΈΠΊΡ€ΠΎΡ„Π»ΠΎΡ€Ρƒ. Из ΠΈΠ½Ρ‚Ρ€Π°ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΎΠ½Π½Ρ‹Ρ… Ρ‚ΠΊΠ°Π½Π΅Π²Ρ‹Ρ… Π±ΠΈΠΎΠΏΡ‚Π°Ρ‚ΠΎΠ² Π΄Π΅Π»Π°Π»ΠΈ ΠΌΠ°Π·ΠΊΠΈ-ΠΎΡ‚ΠΏΠ΅Ρ‡Π°Ρ‚ΠΊΠΈ Π½Π° стСклС, с ΠΎΠΊΡ€Π°ΡˆΠΈΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΏΠΎ Π“Ρ€Π°ΠΌΡƒ, оцСнивая количСство Π»Π΅ΠΉΠΊΠΎΡ†ΠΈΡ‚ΠΎΠ² ΠΈ Π½Π΅ΠΉΡ‚Ρ€ΠΎΡ„ΠΈΠ»ΠΎΠ² Π² ΠΏΠΎΠ»Π΅ зрСния. Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. ΠžΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»Π΅ΠΉ БОЭ, прСсСпсина ΠΈ ΠΈΠ½Ρ‚Π΅Ρ€Π»Π΅ΠΉΠΊΠΈΠ½Π°-6, ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… Π²Ρ‹Ρ…ΠΎΠ΄ΠΈΡ‚ Π·Π° ΠΏΡ€Π΅Π΄Π΅Π»Ρ‹ ΠΎΠ±Ρ‰Π΅ΠΏΡ€ΠΈΠ·Π½Π°Π½Π½Ρ‹Ρ… Π½ΠΎΡ€ΠΌΠ°Π»ΡŒΠ½Ρ‹Ρ… Π·Π½Π°Ρ‡Π΅Π½ΠΈΠΉ ΠΏΡ€ΠΈ Π½Π°Π»ΠΈΡ‡ΠΈΠΈ ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ, ΠΌΠΎΠΆΠ΅Ρ‚ Π±Ρ‹Ρ‚ΡŒ Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄ΠΎΠ²Π°Π½ΠΎ Π² качСствС скрининг-тСста ΠΏΡ€ΠΈ диагностикС ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΎΠ½Π½ΠΎΠΉ ΠΏΡ€ΠΈΡ€ΠΎΠ΄Ρ‹ Π½Π΅ΡΡ‚Π°Π±ΠΈΠ»ΡŒΠ½ΠΎΡΡ‚ΠΈ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚ΠΎΠ² эндопротСза ΠΊΡ€ΡƒΠΏΠ½Ρ‹Ρ… суставов. Π’Ρ‚ΠΎΡ€Ρ‹ΠΌ этапом Π΄ΠΈΡ„Ρ„Π΅Ρ€Π΅Π½Ρ†ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ диагностики сСптичСской ΠΈ асСптичСской Π½Π΅ΡΡ‚Π°Π±ΠΈΠ»ΡŒΠ½ΠΎΡΡ‚ΠΈ ΠΌΠΎΠΆΠ΅Ρ‚ ΡΠ»ΡƒΠΆΠΈΡ‚ΡŒ выявлСниС Π»ΠΈΠΌΡ„ΠΎΠ°Π΄Π΅Π½ΠΎΠΏΠ°Ρ‚ΠΈΠΈ. Ρ‚Ρ€Π΅Ρ‚ΡŒΠΈΠΌ (Π·Π°ΠΊΠ»ΡŽΡ‡ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌ) этапом опрСдСлСния ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΎΠ½Π½ΠΎΠΉ ΠΏΡ€ΠΈΡ€ΠΎΠ΄Ρ‹ Π½Π΅ΡΡ‚Π°Π±ΠΈΠ»ΡŒΠ½ΠΎΡΡ‚ΠΈ являСтся инвазивная ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΈΠΊΠ° с ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ΠΌ уровня Ρ†ΠΈΡ‚ΠΎΠ·Π° с подсчСтом Π½Π΅ΠΉΡ‚Ρ€ΠΎΡ„ΠΈΠ»ΠΎΠ² Π² синовиальной Тидкости

    Evaluation of the effectiveness of the analgesic effect of selective and non-selective cyclooxygenase blockers in the composition of multimodal analgesia after knee joint endoprosthesis replacement

    Get PDF
    The purpose of the work is to compare the effectiveness of anesthesia with the use of a highly specific blocker COX-2 and a dedicated cyclo-oxygenase blocker COX-1 and COX-2 lornoxicam as part of multimodal analgesia in patients after primary knee replacement. The material was the cases of knee prosthesis (N=196) using multimodal analgesia; patients were divided into two groups, depending on the type of anesthesia, in accordance with the developed scheme of pharmacotherapy: I – receiving celecoxib (n=98) and II - lornoxicam (n=98). Methods for evaluating the effectiveness of anesthesia were the visual analogue scale (VAS), the KSS knee joint function evaluation scale before surgery and on the 5th day after it; analysis of the features of early verticalization, the patient's need for additional pain relief after surgery; costs of drug therapy are calculated. Results. Patients of both groups were comparable in age and average duration of hospitalization. The pain syndrome assessment on the VAS scale showed a higher efficacy of pain relief on days 1 and 5 in group II (4.1 Β± 0.1 versus 3.5 Β± 0.1 and 1.9 Β± 0.04 versus 1.6 Β± 0.1 points respectively) (p≀0.05). Evaluation of the functional activity of the prosthetic knee joint on the KSS scale did not reveal any differences between the groups. Of the features of early verticalization on the first day after surgery, a higher percentage of weakness in the legs (79.6%) and nausea (70.4%) was noted in group I, and a higher percentage of dizziness (15.3%) and hemodynamic disorders (6.1% of cases). The cost of providing basic pain therapy in group I was 2.4 times higher than in group II, with the same costs for additional anesthesia with solutions of paracetamol and narcotic analgesics. Conclusions. As part of multimodal analgesia, Lornoxicam showed a higher efficacy in relieving pain syndrome at a low cost of a course of treatment compared with celecoxib.ЦСль Ρ€Π°Π±ΠΎΡ‚Ρ‹ - сравнСниС эффСктивности обСзболивания ΠΏΡ€ΠΈ использовании высокоспСцифичного Π±Π»ΠΎΠΊΠ°Ρ‚ΠΎΡ€Π° Π¦ΠžΠ“-2 цСлСкоксиба ΠΈ нСспСцифичного Π±Π»ΠΎΠΊΠ°Ρ‚ΠΎΡ€Π° циклооксигСназы Π¦ΠžΠ“-1 ΠΈ Π¦ΠžΠ“-2 лорноксикама Π² составС ΠΌΡƒΠ»ΡŒΡ‚ΠΈΠΌΠΎΠ΄Π°Π»ΡŒΠ½ΠΎΠΉ анальгСзии Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² послС ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½ΠΎΠ³ΠΎ эндопротСзирования ΠΊΠΎΠ»Π΅Π½Π½ΠΎΠ³ΠΎ сустава. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»ΠΎΠΌ послуТили случаи протСзирования ΠΊΠΎΠ»Π΅Π½Π½Ρ‹Ρ… суставов (N=196) с использованиСм ΠΌΡƒΠ»ΡŒΡ‚ΠΈΠΌΠΎΠ΄Π°Π»ΡŒΠ½ΠΎΠΉ анальгСзии; Π² зависимости ΠΎΡ‚ Ρ‚ΠΈΠΏΠ° обСзболивания, Π² соотвСтствии с Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚Π°Π½Π½ΠΎΠΉ схСмой Ρ„Π°Ρ€ΠΌΠ°ΠΊΠΎΡ‚Π΅Ρ€Π°ΠΏΠΈΠΈ, ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ Ρ€Π°Π·Π΄Π΅Π»Π΅Π½Ρ‹ Π½Π° Π΄Π²Π΅ Π³Ρ€ΡƒΠΏΠΏΡ‹: I - ΠΏΠΎΠ»ΡƒΡ‡Π°ΡŽΡ‰ΠΈΠ΅ цСлСкоксиб (n=98) ΠΈ II - лорноксикам (n=98). ΠœΠ΅Ρ‚ΠΎΠ΄Π°ΠΌΠΈ ΠΎΡ†Π΅Π½ΠΊΠΈ эффСктивности обСзболивания являлись Π²ΠΈΠ·ΡƒΠ°Π»ΡŒΠ½ΠΎ-аналоговая шкала (ВАШ), шкала ΠΎΡ†Π΅Π½ΠΊΠΈ Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΈ ΠΊΠΎΠ»Π΅Π½Π½ΠΎΠ³ΠΎ сустава KSS Π΄ΠΎ ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΈ ΠΈ Π½Π° 5 сутки послС Π½Π΅Ρ‘; Π°Π½Π°Π»ΠΈΠ· особСнностСй Ρ€Π°Π½Π½Π΅ΠΉ Π²Π΅Ρ€Ρ‚ΠΈΠΊΠ°Π»ΠΈΠ·Π°Ρ†ΠΈΠΈ, потрСбности ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π° Π² Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠΌ ΠΎΠ±Π΅Π·Π±ΠΎΠ»ΠΈΠ²Π°Π½ΠΈΠΈ послС ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΈ; рассчитаны Π·Π°Ρ‚Ρ€Π°Ρ‚Ρ‹ Π½Π° ΠΌΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½Ρ‚ΠΎΠ·Π½ΡƒΡŽ Ρ‚Π΅Ρ€Π°ΠΏΠΈΡŽ. Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. ΠŸΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ ΠΎΠ±Π΅ΠΈΡ… Π³Ρ€ΡƒΠΏΠΏ Π±Ρ‹Π»ΠΈ сопоставимы ΠΏΠΎ возрасту ΠΈ срСднСй Π΄Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ госпитализации. ΠΎΡ†Π΅Π½ΠΊΠ° Π±ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ синдрома ΠΏΠΎ шкалС ВАШ ΠΏΠΎΠΊΠ°Π·Π°Π»Π° Π±ΠΎΠ»Π΅Π΅ Π²Ρ‹ΡΠΎΠΊΡƒΡŽ ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ купирования Π±ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ синдрома Π½Π° 1 ΠΈ 5 сутки Π²ΠΎ II Π³Ρ€ΡƒΠΏΠΏΠ΅ (4,1Β±0,1 ΠΏΡ€ΠΎΡ‚ΠΈΠ² 3,5Β±0,1 ΠΈ 1,9Β±0,04 ΠΏΡ€ΠΎΡ‚ΠΈΠ² 1,6Β±0,1 Π±Π°Π»Π»Π° соотвСтствСнно) (p≀0,05). ΠΎΡ†Π΅Π½ΠΊΠ° Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΎΠ½Π°Π»ΡŒΠ½ΠΎΠΉ активности ΠΏΡ€ΠΎΡ‚Π΅Π·ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΊΠΎΠ»Π΅Π½Π½ΠΎΠ³ΠΎ сустава ΠΏΠΎ шкалС KSS Π½Π΅ выявила Ρ€Π°Π·Π»ΠΈΡ‡ΠΈΠΉ ΠΌΠ΅ΠΆΠ΄Ρƒ Π³Ρ€ΡƒΠΏΠΏΠ°ΠΌΠΈ. особСнности Ρ€Π°Π½Π½Π΅ΠΉ Π²Π΅Ρ€Ρ‚ΠΈΠΊΠ°Π»ΠΈΠ·Π°Ρ†ΠΈΠΈ Π² 1 сутки послС ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΈ: Π² I Π³Ρ€ΡƒΠΏΠΏΠ΅ - Π±ΠΎΠ»Π΅Π΅ высокий ΠΏΡ€ΠΎΡ†Π΅Π½Ρ‚ слабости Π² Π½ΠΎΠ³Π°Ρ… (79,6%) ΠΈ Ρ‚ΠΎΡˆΠ½ΠΎΡ‚Ρ‹ (70,4%), Π²ΠΎ II - Π²Ρ‹ΡˆΠ΅ ΠΏΡ€ΠΎΡ†Π΅Π½Ρ‚ головокруТСния (15,3%) ΠΈ Π½Π°Ρ€ΡƒΡˆΠ΅Π½ΠΈΠΉ Π³Π΅ΠΌΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ (6,1% случаСв). Π—Π°Ρ‚Ρ€Π°Ρ‚Ρ‹ Π½Π° обСспСчСниС Π±Π°Π·ΠΎΠ²ΠΎΠΉ ΠΎΠ±Π΅Π·Π±ΠΎΠ»ΠΈΠ²Π°ΡŽΡ‰Π΅ΠΉ Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π² I Π³Ρ€ΡƒΠΏΠΏΠ΅ Π² 2,4 Ρ€Π°Π·Π° прСвысили ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΡŒ II Π³Ρ€ΡƒΠΏΠΏΡ‹, ΠΏΡ€ΠΈ Ρ€Π°Π²Π½Ρ‹Ρ… Π·Π°Ρ‚Ρ€Π°Ρ‚Π°Ρ… Π½Π° Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ΅ ΠΎΠ±Π΅Π·Π±ΠΎΠ»ΠΈΠ²Π°Π½ΠΈΠ΅ растворами ΠΏΠ°Ρ€Π°Ρ†Π΅Ρ‚Π°ΠΌΠΎΠ»Π° ΠΈ наркотичСских Π°Π½Π°Π»ΡŒΠ³Π΅Ρ‚ΠΈΠΊΠΎΠ². Π’Ρ‹Π²ΠΎΠ΄Ρ‹. Лорноксикам Π² составС ΠΌΡƒΠ»ΡŒΡ‚ΠΈΠΌΠΎΠ΄Π°Π»ΡŒΠ½ΠΎΠΉ анальгСзии ΠΏΠΎΠΊΠ°Π·Π°Π» Π±ΠΎΠ»Π΅Π΅ Π²Ρ‹ΡΠΎΠΊΡƒΡŽ ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ купирования Π±ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ синдрома ΠΏΡ€ΠΈ Π½ΠΈΠ·ΠΊΠΎΠΉ стоимости курсового лСчСния ΠΏΠΎ ΡΡ€Π°Π²Π½Π΅Π½ΠΈΡŽ с цСлСкоксибом

    Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2

    No full text
    The oncogene Tpr-Met is a constitutively active form of the hepatocyte growth factor/scatter factor (HGF/SF) receptor Met. It comprises the intracellular moiety of Met linked to the dimerization domain of the nuclear envelope protein Tpr, thus functioning as a constitutively activated Met. HGF/SF is responsible for various biological processes including angiogenesis and wound healing, in which secreted serine protease urokinase-type plasminogen activator (uPA) is implicated. The action of HGF/SF on cells is mediated by the autophosphorylation of Met on two carboxyterminal tyrosine residues, Y1349VHVNATVY1356VNV. The two tyrosine residues provide docking sites for various effector molecules, suggesting that multiple signaling pathways are activated to exert biological effects of HGF/SF [Ponzetto et al., Cell (1994) 77: 261]. We found that Tpr-Met efficiently activates the uPA gene via a SOS/Ras/extracellular signal regulated kinase (ERK)-dependent signaling pathway. Mutation of Y1356, which abrogates GRB2 binding, reduced the induction to half of the control level, while mutation of Y1349 showed little effect on uPA induction, suggesting an important but partly replaceable role for GRB2 in Met-dependent uPA gene induction. Mutation of both Y1349VHV and Y1356VNV into optimal PI 3-kinase sites resulted in a residual induction of about one quarter of the control level, suggesting a potential role for PI 3-kinase. Dose-response analysis of the Tpr-Met showed a biphasic curve. These results suggest that the interplay among different signaling molecules on the receptor is important for full induction of the pathway leading to the activation of the uPA gene
    corecore